Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Issue 6 (16th February 2015)

• Record Type: Journal Article
• Authors: Wetmore, Cynthia; Boyett, James; Li, Shaoyu; Lin, Tong; Bendel, Anne; Gajjar, Amar; Orr, Brent A.
• Is Part Of: Neuro-oncology. Volume 17:Issue 6(2015:Jun.)
• Page Start: 882
• Page End: 888
• Publication Date: 2015-02-16
• Subjects: ATRT -- Aurora kinase A -- brain tumor -- pediatric -- targeted therapy; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/nov017
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Background: Aurora Kinase A ( AURKA ) encodes a protein that regulates the formation and stability of the mitotic spindle and is highly active in atypical teratoid rhabdoid tumors (ATRT) through loss of the INI1 tumor suppressor gene. Alisertib (MLN8237) inhibits AURKA in vitro and in vivo. Given the strong preclinical data supporting the use of alisertib for ATRT patients, we sought and obtained permission to use alisertib in single patient treatment plans for 4 recurrent pediatric ATRT patients. Methods: Patients with recurrent or progressive ATRT received alisertib 80 mg/m 2 by mouth once daily for 7 days of a 21-day treatment cycle. Disease evaluation (MRI of brain and spine and lumbar puncture) was done after 2 cycles of alisertib and every 2–3 cycles thereafter for as long as the patients remained free from tumor progression. Results: Four patients with median age of 2.5 years (range, 1.39–4.87 y) at diagnosis received alisertib 80 mg/m 2 by mouth once daily for 7 days of a 21-day treatment cycle, and all 4 patients had disease stabilization and/or regression after 3 cycles of alisertib therapy. Two patients continued to have stable disease regression for 1 and 2 years, respectively, on therapy. Conclusions: Single-agent alisertib produced marked and durable regression in disease burden, as detected by brain and spine MRI and by evaluation of spinal fluid cytology. Alisertib has moderate but manageable toxicities, and its chronic administration appears feasible in this pediatric population. These novel data support the incorporation of alisertib in future therapeutic trials for children with ATRT.